WuXi PharmaTech Cayman Inc

Type: Company
Name: WuXi PharmaTech Cayman Inc (WuXi PharmaTech (Cayman) Inc)
First reported 1 hour ago - Updated 1 hour ago - 1 reports

WuXi PharmaTech Raised to Conviction-Buy at Goldman Sachs (WX)

Separately, analysts at Zacks upgraded shares of WuXi PharmaTech from an “underperform” rating to a “neutral” rating in a research note on Wednesday, July 16th. They now have a $33.50 price target on the stock. Two analysts have rated the stock with a ... [Published American Banking News - Stock Ratings - 1 hour ago]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Asian ADRs Lower Despite Renewable Energy Gains

In Southern Asia, business process management company WNS Holdings ( WNS ) was trading 1.3% lower and Indian news and shopping web portal Rediff.com India (REDF) was down 1.2%. while SIFY (SIFY), an integrated network and electronic commerce services ... [Published Nasdaq - Sep 22 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

Avelas Biosciences Extends Series B Financing to $7.4 Million

Avelas Biosciences, an in vivo cancer diagnostic company for oncologic surgeries, announced that it has closed on the second tranche of its Series B financing bringing the total funds raised in the round to $7.4 million. Participants in the financing ... [Published PE Hub Blog - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Eye on WuXi PharmaTech (Cayman) Inc. (WX)

(AdviceTrade via COMTEX News Network) -- by Sinisa Persic, www.TraderHRan AdviceTrade.com publicationWuXi PharmaTech (Cayman) Inc. (WX) is positioned to break out of a two-week flag that has been a rest period after it ran up more than 10% in mid Aug ... [Published PredictWallStreet - Sep 03 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Russian VC invests in U.S. aldehyde metabolism therapy

RusnanoMedInvest (RMI), a portfolio VC fund of Russia’s Rusnano, has led a $24m round of Series B investment in Aldea Pharmaceuticals, a U.S.-based developer of novel therapeutics to treat aldehyde metabolism disorders, the American company announced ... [Published Marchmont.ru - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

WuXi PharmaTech reports lower Q2 net income, provides annual outlook

WuXi PharmaTech Inc. has reported a net income of $29.34 million, or $0.41 per diluted ADS, for the second quarter ended June 30, 2014, compared to $29.62 million, or $0.41 per diluted ADS, for the same quarter ended June 30, 2013.For 2014, the company ... [Published Individual.com - Sep 01 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Pre-VC rounds are shaking up early-stage funding

The Sense sleep tracking device has been backed by angel investors and crowdfunding campaigns. ’s Evelyn Rusli reports that startups are tapping new sources of early-stage funding, including ad hoc networks of wealthy tech executives doing some investing ... [Published Impact Lab - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Canaan, Correlation Ventures in $24m Series B for pharma company

Canaan Partners and Correlation Ventures have re-upped in a $24m Series B financing round for medical company Aldea Pharmaceuticals .Healthcare-focused RusnanoMedInvest and WuXi PharmaTech Corporate Ventures invested in the company for the first time ... [Published AltAssets.net - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Aldea Closes $24mn Series B Financing

Aldea Pharmaceuticals has closed a US$24 million Series B equity financing. The financing included new investors RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures. All previous investors including Canaan Partners andCorrelation Ventures also ... [Published PharmaAsia - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 5 reports

Aldea Pharmaceuticals Takes $24M

Redwood City-based Aldea Pharmaceuticals said this morning that it has raised $24M in a Series B funding round. The funding came from RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures, along with prior investors Canaan Partners and Correlation ... [Published Silicontap - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

WuXi PharmaTech appoints new independent board director

WuXi PharmaTech Cayman Inc., a provider of contract research outsourcing services, has appointed Walter Kwauk as an independent director to its board of directors. Mr. Kwauk will serve on the Audit Committee. Mr. Kwauk is currently a senior consultant ... [Published Individual.com - Aug 25 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 2 reports

Buyers Accumulate Shares of WuXi PharmaTech Cayman, Up 7.2%

Written on Thu, 08/14/2014 - 12:29pmBy Shiri GuptaOne of today's stocks on the move is WuXi PharmaTech Cayman ( NYSE:WX ), up 7.2% to $34.54. The S&P is currently trading 0.3% higher to 1,952 and the Dow Jones Industrial Average is trading 0.2% higher ... [Published Comtex SmarTrend - Aug 14 2014]

Quotes

"WuXi PharmaTech had another solid performance in the second quarter" said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech
...been prepared in accordance with United Kingdom Generally Accepted Accounting Practice (UK GAAP) and with the Statement of Recommended Practice, "Financial Statements of Investment Trust Companies and Venture Capital Trusts" issued in January 2009 and the Interim Management Report as set out above includes a fair review of the information required by 4.2.7R and 4.2...
...suffering from co-morbidities such as trauma, as well as benefiting the system as a whole," said William Yelle, chief executive officer of Aldea. "We also have the opportunity to apply our scientific approach in the treatment of patients with Fanconi anemia, a rare genetic disease characterized by chromosomal instability, bone marrow failure and an increased risk of cancer. The funds we have secured with this financing should allow us to generate proof-of-concept data in both of these indications."
...Ge Li, Chairman and CEO of WuXi PharmaTech. "With his help, WuXi will continue to advance in its mission to build a comprehensive, integrated open-access R&D services platform."

More Content

All (88) | News (48) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (2) | Press Releases (8)
sort by: Date | Relevance
WuXi PharmaTech Raised to Conviction-Buy at Gol... [Published American Banking News - Stock Ratings - 1 hour ago]
HPAPIs and Cytotoxic Drugs Manufacturing Market... [Published Nation's Restaurant News - 5 hours ago]
Asian ADRs Lower Despite Renewable Energy Gains [Published Nasdaq - Sep 22 2014]
Biggest Movers in Healthcare Stocks Now – CLVS ... [Published InvestorPlace.com - Sep 18 2014]
Avelas Biosciences Raises $7.4M in Funding Round [Published San Diego Business Journal - Sep 10 2014]
Avelas Biosciences Extends Series B Financing t... [Published PE Hub Blog - Sep 10 2014]
Healthcare Industry Consolidation: The Rise Of ... [Published Seeking Alpha - Sep 10 2014]
Avelas Closes Round, Advancing Biologic That Il... [Published Xconomy - Sep 10 2014]
Avelas Biosciences Boosts Series B to $7.4M [Published Dow Jones Financial Information Services - Sep 10 2014]
Hottest Healthcare Stocks Now – PTCT NPSP UTHR OPK [Published InvestorPlace.com - Sep 09 2014]
Eye on WuXi PharmaTech (Cayman) Inc. (WX) [Published PredictWallStreet - Sep 03 2014]
Russian VC invests in U.S. aldehyde metabolism ... [Published Marchmont.ru - Sep 01 2014]
WuXi PharmaTech reports lower Q2 net income, pr... [Published Individual.com - Sep 01 2014]
Half Yearly Report [Published MoneyAM - Aug 29 2014]
Pre-VC rounds are shaking up early-stage funding [Published Impact Lab - Aug 28 2014]
Canaan, Correlation Ventures in $24m Series B f... [Published AltAssets.net - Aug 26 2014]
Aldea Closes $24mn Series B Financing [Published PharmaAsia - Aug 26 2014]
Aldea Pharmaceuticals Takes $24M [Published Silicontap - Aug 25 2014]
Aldea raises $24M for drug that targets severe ... [Published MedCity News - Aug 25 2014]
Redwood City Startup, Aldea Pharmaceuticals, Re... [Published BioSpace - Aug 25 2014]
Aldea Pharmaceuticals secures $24 million in Se... [Published Individual.com - Aug 25 2014]
WuXi PharmaTech appoints new independent board ... [Published Individual.com - Aug 25 2014]
Aldea raises $24M to push alcohol-poisoning ant... [Published FierceBiotech - Aug 25 2014]
Startup Aldea Pharma snags $24M for a quick way... [Published Business First of Buffalo - Aug 25 2014]
The Daily Startup: Pre-VC Rounds Shaking Up Ear... [Published WSJ.com: Venture Capital Dispatch - Aug 25 2014]
Aldea Pharmaceuticals snags $24 mln Series B [Published PE Hub Blog - Aug 25 2014]
Aldea Pharmaceuticals Closes $24 Million Series... [Published CW 50 Detroit - Aug 25 2014]
WUXI PHARMATECH CAYMAN : Announces Second-Quart... [Published 4 Traders - Aug 21 2014]
Hottest Healthcare Stocks Now – THOR GSK ESRX CNC [Published InvestorPlace.com - Aug 21 2014]
3 red-hot biotechnology stocks [Published MSN Money - Aug 19 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Avelas Biosciences Extends Series B Financing t... [Published PE Hub Blog - Sep 10 2014]
Avelas Biosciences, an in vivo cancer diagnostic company for oncologic surgeries, announced that it has closed on the second tranche of its Series B financing bringing the total funds raised in the round to $7.4 million. Participants in the financing ...
The Daily Startup: Pre-VC Rounds Shaking Up Ear... [Published WSJ.com: Venture Capital Dispatch - Aug 25 2014]
The $99 Sense sleep tracking device has been backed by angel investors and crowdfunding campaigns so far.Hello Startups are tapping new sources of early-stage funding, including ad hoc networks of wealthy tech executives doing some investing on the side, ...
Aldea Pharmaceuticals snags $24 mln Series B [Published PE Hub Blog - Aug 25 2014]
Aldea Pharmaceuticals said Monday that it has received $24 million in Series B financing. The investors included RusnanoMedInvest, WuXi PharmaTech Corporate Ventures, Canaan Partners and Correlation Ventures. Based in Redwood City, Calif., Aldea ...
WuXi PharmaTech Announces Second-Quarter 2014 R... [Published PR Newswire: Financial Services - Aug 13 2014]
SHANGHAI, Aug. 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, ...
WuXi PharmaTech Announces Appointment of Walter... [Published PR Newswire: General Business - Aug 08 2014]
SHANGHAI, Aug. 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Scheduled Conference Calls and Managements Chan... [Published Financial Services - Jul 14 2014]
Collaborations, Clinical Study Results, and Lab... [Published Financial Services - Jun 25 2014]
Health Care Sector Stocks Coverage -- Research ... [Published Financial Services - Jun 18 2014]
Strategic Collaborations, Certified Solutions, ... [Published Financial Services - Jun 05 2014]
Targos Molecular Pathology GmbH and WuXi Pharma... [Published Financial Services - May 23 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.